3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Sarcoma
3
Lung Neoplasms
3
Breast Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Neuroectodermal Tumors
2
Nervous System Diseases
2
Neoplasms, Neuroepithelial
2
Neoplasms, Nerve Tissue
2
Liver Neoplasms
2
Head and Neck Neoplasms
2
Gliosarcoma
2
Glioma
2
Glioblastoma
2
Colorectal Neoplasms
2
Carcinoma
2
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Gastrointestinal Neoplasms
1
Disease
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
4
Sirolimus
3
pembrolizumab
2
fludarabine
2
etoposide phosphate
2
Mesna
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Celecoxib
2
Busulfan
2
ripretinib
1
repotrectinib
1
pegylated granulocyte colony-stimulating factor
1
interferon gamma-1b
1
fludarabine phosphate
1
bintrafusp alfa protein, human
1
Vorinostat
1
Ursodeoxycholic Acid
1
Topotecan
1
Thrombopoietin
1
Thiotepa
1
Therapeutics
1
Tetrahydrouridine
1
Stem Cell Transplantation
1
Simvastatin
1
Radiotherapy, Image-Guided
1
Radiation
1
Psychiatric Rehabilitation
1
Plicamycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Germ Cell and Embryonal
×
Oncolytic Virotherapy
×
Sarcoma
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled